A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain

Update Il y a 4 ans
Reference: EUCTR2007-001139-71

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare the analgesic efficacy and the safety of ABT-894 (1 mg, 2 mg, or 4 mg capsules) administered twice daily (BID) to placebo in the treatment of diabetic neuropathic pain (DNP). Duloxetine 60 mg administered once daily (QD) will be assessed for assay sensitivity.


Inclusion criteria

  • Diabetic Neuropathic Pain